Form: S-8

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

November 7, 2024


Exhibit 107

Calculation of Filing Fee Table

Form S-8
(Form Type)

Avalo Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type Security Class Title Fee Calculation Rule
Amount Registered(1)
Proposed Maximum Offering Price Per Share(4)
Maximum Aggregate Offering Price(4)
Fee Rate Amount of Registration Fee
Equity Common Stock, $0.001 par value per share Rule 457(h)
234,000 shares(2)
$ 12.65  $ 2,960,100  $ 0.0001531  $ 453 
Equity Common Stock, $0.001 par value per share Rule 457(h)
150,000 shares(3)
$ 13.43  $ 2,014,500  $ 0.0001531  $ 308 
Total Offering Amounts 384,000 shares $ 4,974,600  761
Total Fee Offsets $ — 
Net Fee Due $ 761 
(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 shall also cover any additional shares of Avalo Therapeutics, Inc.’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock.
(2) Represents 234,000 shares of Common Stock issuable under the inducement stock option award pursuant to a stock option agreement entered into with Mittie Doyle on July 15, 2024.
(3) Represents 150,000 shares of Common Stock issuable under the inducement stock option award pursuant to a stock option agreement entered into with Paul Varki on June 24, 2024.
(4) Such shares are issuable upon exercise of outstanding options with a fixed exercise price. Pursuant to Rule 457(h) of the Securities Act, the aggregate offering price and the fee have been computed upon the basis of the price at which the option may be exercised, which was the closing price of a share of Common Stock on the date of grant of such option as reported on the Nasdaq Capital Market.